Hennion & Walsh Asset Management Inc. Has $3.54 Million Position in Taysha Gene Therapies, Inc. $TSHA

Hennion & Walsh Asset Management Inc. lifted its holdings in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 32.6% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 519,120 shares of the company’s stock after acquiring an additional 127,644 shares during the period. Hennion & Walsh Asset Management Inc. owned approximately 0.18% of Taysha Gene Therapies worth $3,535,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Militia Capital Management LLC bought a new stake in shares of Taysha Gene Therapies during the 1st quarter valued at about $208,000. Seven Fleet Capital Management LP increased its holdings in Taysha Gene Therapies by 274.2% in the first quarter. Seven Fleet Capital Management LP now owns 625,708 shares of the company’s stock worth $2,797,000 after purchasing an additional 458,485 shares in the last quarter. Bank of America Corp DE increased its holdings in Taysha Gene Therapies by 45.5% in the first quarter. Bank of America Corp DE now owns 1,677,046 shares of the company’s stock worth $7,496,000 after purchasing an additional 524,366 shares in the last quarter. ADAR1 Capital Management LLC lifted its stake in Taysha Gene Therapies by 19.4% in the first quarter. ADAR1 Capital Management LLC now owns 2,979,429 shares of the company’s stock valued at $13,318,000 after buying an additional 483,620 shares during the period. Finally, The Manufacturers Life Insurance Company lifted its stake in Taysha Gene Therapies by 48.1% in the first quarter. The Manufacturers Life Insurance Company now owns 99,371 shares of the company’s stock valued at $444,000 after buying an additional 32,286 shares during the period. 77.70% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Taysha Gene Therapies

In other Taysha Gene Therapies news, insider Sukumar Nagendran sold 200,000 shares of the firm’s stock in a transaction on Friday, July 10th. The shares were sold at an average price of $6.24, for a total value of $1,248,000.00. Following the transaction, the insider directly owned 936,410 shares of the company’s stock, valued at approximately $5,843,198.40. This trade represents a 17.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 3.48% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on TSHA shares. Needham & Company LLC reaffirmed a “buy” rating and set a $12.00 price objective on shares of Taysha Gene Therapies in a research report on Tuesday, June 30th. Citigroup reiterated an “outperform” rating on shares of Taysha Gene Therapies in a research note on Tuesday, June 23rd. The Goldman Sachs Group boosted their target price on shares of Taysha Gene Therapies from $11.00 to $13.00 and gave the company a “buy” rating in a research report on Tuesday, July 21st. Weiss Ratings reissued a “sell (d-)” rating on shares of Taysha Gene Therapies in a research note on Wednesday, June 24th. Finally, Pivotal Research set a $14.00 price target on shares of Taysha Gene Therapies in a report on Tuesday, June 23rd. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $12.77.

Taysha Gene Therapies Stock Performance

NASDAQ TSHA opened at $6.37 on Tuesday. The company has a market cap of $1.83 billion, a P/E ratio of -16.76 and a beta of 1.22. The company has a fifty day simple moving average of $6.06 and a 200 day simple moving average of $5.45. The company has a current ratio of 14.04, a quick ratio of 14.04 and a debt-to-equity ratio of 0.23. Taysha Gene Therapies, Inc. has a 12-month low of $2.68 and a 12-month high of $7.30.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.